Monday April 13, 6:00 am Eastern Time Company Press Release SOURCE: Zila, Inc.
Zila's OraTest(TM) Oral Cancer Detection System Approved In Several European Union Nations
PHOENIX, April 13 /PRNewswire/ -- Zila, Inc. (Nasdaq: ZILA - news), international provider of healthcare products for dental/medical professionals and consumers, announced that its oral cancer detection system, OraTest(TM), has won regulatory approval in Portugal, Belgium, Luxembourg, Holland, Finland and Greece. The approvals were granted Thursday under European Union drug approval rules, based upon the United Kingdom's [NYSE:UKM - news] approval of OraTest in 1995. Applications are pending in the remainder of the EU member nations.
Zila President Joseph Hines said, ``The potential EU market for OraTest is greater than that of the United States, owing to the EU's larger population and higher smoking rates. (Tobacco use and heavy drinking are the primary causes of oral cancer.) We look forward to OraTest saving lives throughout the world.''
Zila's British licensee, Stafford-Miller Ltd. (a division of Block Drug Company), will launch an intensive marketing campaign for OraTest (known in the UK as OraScreen(TM)) on April 24, targeting dentists in general practice throughout the UK. Stafford-Miller has been working with UK dental specialists for two years, laying the groundwork for the upcoming mass marketing effort.
OraTest is a patented five-minute mouthrinse sequence that has been shown to be 100 percent sensitive for squamous cell carcinoma (oral cancer). European nations have approved its use for screening, detection of second primary lesions, and defining margins of lesions for biopsy and surgery. OraTest is also available in Australia, Canada, Taiwan, Hungary, Bermuda, Barbados and the Bahamas. FDA approval is pending.
Zila, Inc., markets pharmaceutical, biomedical, dental and nutritional products to professionals and consumers through seven operating groups: Zila Biomedical is introducing the OraTest oral cancer detection system worldwide; Zila Manufacturing produces the only pharmaceutical-grade toluidine blue
Zila(R) Tolonium Chloride; Zila Pharmaceuticals markets prescription and non-prescription oral healthcare products; Zila Dental Supply is a national dental supplies distributor; PracticeWorks develops and markets proprietary dental practice management software; Cygnus Imaging manufactures and markets intraoral video camera and digital x-ray systems; and Oxycal Laboratories manufactures and supplies Ester-C(R) vitamin products worldwide.
This document contains forward-looking statements which are based on Zila's expectations and are subject to various business risks and uncertainties, some of which are beyond Zila's control. Actual results could differ materially from these forward-looking statements as a result of such risks. There can be no assurances that the forward looking statements contained herein will in fact transpire or prove to be accurate.
Media Relations Contact: Annie Truncale/[email protected]
RSS